The test is available in nearly 200 countries, and many centers around the world are authorized to translate, adapt, and validate the test for their specific linguistic, cultural, and educational differences. In 2003, after analysis of the 2000 study results, a few elements of the test were optmized, and a new validation study was completed in 2003-2004, which confirmed the test’s discriminatory ability to distinguish Normal controls, from subjects with Mild Cognitive Impairment or Mild Alzheimer’s disease. MoCA performance to distinguish the two groups was excellent.
All subjects were classified as cognitively intact or impaired based on a gold standard neuropsychological assessment. MoCA is the most sensitive test available for detecting Alzheimer’s disease, measuring executive functions and multiple cognitive domains which are important components not measured by the MMSE.įrom 1992 to 2000, MoCA went through many versions and adaptations before it was first validated in 2000 on a consecutive group of subjects that were referred to a memory clinic. MoCA-also known as Montreal Cognitive Assessment or the MoCA Test-is a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care.